Paying users zone. Data is covered by 
.
Get 1 month access to Biogen Inc. for $15.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
Biogen Inc. (BIIB)
Profitability Analysis
Quarterly Data
Difficulty: Beginner
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Ratios (Summary)
Biogen Inc., profitability ratios (quarterly data)
Based on: 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).
| Ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Biogen Inc.’s gross profit margin deteriorated from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Biogen Inc.’s operating profit margin deteriorated from Q4 2018 to Q1 2019 but then improved from Q1 2019 to Q2 2019 exceeding Q4 2018 level. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Biogen Inc.’s net profit margin improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
| Ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Biogen Inc.’s ROE deteriorated from Q4 2018 to Q1 2019 but then improved from Q1 2019 to Q2 2019 exceeding Q4 2018 level. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Biogen Inc.’s ROA improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
Gross Profit Margin
Biogen Inc., gross profit margin calculation (quarterly data)
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Gross profit | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenues | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ratio | |||||||||||||||||||||||
| Gross profit margin1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benchmarks | |||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).
1 Q2 2019 Calculation
Gross profit margin = 100
× (Gross profitQ2 2019
+ Gross profitQ1 2019
+ Gross profitQ4 2018
+ Gross profitQ3 2018)
÷ (RevenuesQ2 2019
+ RevenuesQ1 2019
+ RevenuesQ4 2018
+ RevenuesQ3 2018)
= 100
× ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Biogen Inc.’s gross profit margin deteriorated from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
Operating Profit Margin
Biogen Inc., operating profit margin calculation (quarterly data)
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Income from operations | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenues | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ratio | |||||||||||||||||||||||
| Operating profit margin1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benchmarks | |||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).
1 Q2 2019 Calculation
Operating profit margin = 100
× (Income from operationsQ2 2019
+ Income from operationsQ1 2019
+ Income from operationsQ4 2018
+ Income from operationsQ3 2018)
÷ (RevenuesQ2 2019
+ RevenuesQ1 2019
+ RevenuesQ4 2018
+ RevenuesQ3 2018)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Biogen Inc.’s operating profit margin deteriorated from Q4 2018 to Q1 2019 but then improved from Q1 2019 to Q2 2019 exceeding Q4 2018 level. |
Net Profit Margin
Biogen Inc., net profit margin calculation (quarterly data)
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net income attributable to Biogen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenues | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ratio | |||||||||||||||||||||||
| Net profit margin1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benchmarks | |||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).
1 Q2 2019 Calculation
Net profit margin = 100
× (Net income attributable to Biogen Inc.Q2 2019
+ Net income attributable to Biogen Inc.Q1 2019
+ Net income attributable to Biogen Inc.Q4 2018
+ Net income attributable to Biogen Inc.Q3 2018)
÷ (RevenuesQ2 2019
+ RevenuesQ1 2019
+ RevenuesQ4 2018
+ RevenuesQ3 2018)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Biogen Inc.’s net profit margin improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |
Return on Equity (ROE)
Biogen Inc., ROE calculation (quarterly data)
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net income attributable to Biogen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Biogen Inc. shareholders’ equity | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ratio | |||||||||||||||||||||||
| ROE1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benchmarks | |||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).
1 Q2 2019 Calculation
ROE = 100
× (Net income attributable to Biogen Inc.Q2 2019
+ Net income attributable to Biogen Inc.Q1 2019
+ Net income attributable to Biogen Inc.Q4 2018
+ Net income attributable to Biogen Inc.Q3 2018)
÷ Total Biogen Inc. shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Biogen Inc.’s ROE deteriorated from Q4 2018 to Q1 2019 but then improved from Q1 2019 to Q2 2019 exceeding Q4 2018 level. |
Return on Assets (ROA)
Biogen Inc., ROA calculation (quarterly data)
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net income attributable to Biogen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total assets | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ratio | |||||||||||||||||||||||
| ROA1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benchmarks | |||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AbbVie Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Allergan PLC | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amgen Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bristol-Myers Squibb Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Celgene Corp. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Eli Lilly & Co. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gilead Sciences Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Johnson & Johnson | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Merck & Co. Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pfizer Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Regeneron Pharmaceuticals Inc. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).
1 Q2 2019 Calculation
ROA = 100
× (Net income attributable to Biogen Inc.Q2 2019
+ Net income attributable to Biogen Inc.Q1 2019
+ Net income attributable to Biogen Inc.Q4 2018
+ Net income attributable to Biogen Inc.Q3 2018)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
| Ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Biogen Inc.’s ROA improved from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019. |